Jesper Brandgaard/LinkedIn
Dec 7, 2025, 05:45
Jesper Brandgaard: Novo Nordisk Haemophilia Foundation is Evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Jesper Brandgaard, Chairman at LEO Pharma, posted on LinkedIn:
“As the former President of the Council, I am absolutely delighted to share that the Novo Nordisk Haemophilia Foundation is evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation. It’s truly inspiring to witness the mission grow to support even more lives. A huge thank you to the Novo Nordisk Foundation for joining as an accelerating partner on this ambitious journey to quadruple the annual beneficiaries by 2030.
Congratulations to the entire NNHF Council and Team – here’s to an exciting new era ahead!”
Get the latest with Hemostasis Today.
-
Apr 26, 2026, 05:43Pablo Corral: The Interplay Between Lipoprotein(a) and Interleukin-6 in Determining Primary Cardiovascular Risk
-
Apr 26, 2026, 05:37Bishal Gyawali: A Practical Guide to Reading Clinical Trial Reports
-
Apr 26, 2026, 05:32Expert Care When It Matters Most – Johns Hopkins All Children’s Hospital
-
Apr 26, 2026, 05:20Honoring the 2025 Excellence in Patient Advocacy Award – The Max Foundation
-
Apr 26, 2026, 05:03Ursula Porage Dona: From Inspiring Knowledge to Hearing Firsthand Stories
-
Apr 26, 2026, 04:34ASH – ISTH Pediatric VTE Prophylaxis Guidelines in The ASCO Post
-
Apr 26, 2026, 03:27Gianpiero Gravante: Comparative Evaluation of Surgical Strategies for Grade III Hemorrhoidal Disease
-
Apr 25, 2026, 17:10Abdul Mannan: 10-Minute FVIII Inhibitor Screening Test
-
Apr 25, 2026, 16:55Connie Montgomery: Highlights from the Hemophilia Federation of America Symposium 2026